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Abstract
Background: Autism Spectrum Disorder (ASD) is a neuro-developmental disorder that affects communication and
behavior with a prevalence of approximately 1% worldwide. Health outcomes of interventions for ASD are largely
Participant Reported Outcomes (PROs). Specific guidelines can help support the best care for people with ASD to
optimize these health outcomes but they have to adhere to standards for their development to be trustworthy.
Objective: The goal of this article is to describe the new methodological standards of the Italian National Institute
of Health and novel aspects of this guideline development process. This article will serve as a reference standard for
future guideline development in the Italian setting.
Methods: We applied the new standards of the Italian National Institute of Health to the two guidelines on
diagnosis and management of children/adolescents and adults with ASD, with a focus on the scoping, panel
composition, management of conflict of interest, generation and prioritization of research questions, early
stakeholders’ involvement, and PROs. Recommendations are based on the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) Evidence-to-Decision frameworks.
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Results: Following a public application process, the ISS established two multidisciplinary panels including people
with ASD and/or their caregivers. Seventy-nine research questions were identified as potentially relevant for the
guideline on children and adolescents with ASD and 31 for the one on adults with ASD. Questions deemed to
have the highest priority were selected for inclusion in the guidelines. Other stakeholders valued their early
involvement in the process which will largely focus on PROs. The panels then successfully piloted the development
of recommendations using the methodological standards and process set by the ISS with a focus on PROs.
Conclusions: In this article, we describe the development of practice guidelines that focus on PROs for the
diagnosis and management of ASD based on novel methods for question prioritization and stakeholder
involvement. The recommendations allow for the adoption or adaptation to international settings.
Keywords: Autism Spectrum disorder, Italian National Institute of health, Italian national guidelines system, GRADE
approach, Healthcare decision, Diagnosis, Treatment, Recommendations, Guideline
Introduction
Clinical Practice Guidelines (CPGs) are statements
containing recommendations for clinical practice or
public health policy. A recommendation describes, for
the intended end-user of the guideline, what he or
she can or should do in specific situations to achieve
the best health outcomes possible, individually or
collectively [1]. Besides their primary objective to im-
prove health outcomes through the promotion of
evidence-based care and clinical pathways, CPGs also
serve as a resource for patients, caregivers, policy-
makers, researchers and regulatory bodies.
Clinical practice guidelines in Italy
Following novel national regulations on responsibil-
ities of healthcare professionals [2], the Italian Na-
tional Institute of Health (Istituto Superiore di Sanità,
ISS) through the recently instituted Centre for Clinical
Excellence, Quality and Safety of Care (Centro Nazio-
nale per l’Eccellenza Clinica, la Qualità e la Sicurezza
delle Cure, CNEC), is responsible for the governance
of the Italian guidelines production process [3]. In this
framework, the new Italian National Guidelines Sys-
tem (Sistema Nazionale Linee Guida, SNLG) was
established as the pivotal instrument to promote an ef-
ficient production mechanism of good quality national
guidelines, and the methodological standards recom-
mended for the development and evaluation of CPGs
were set. Based on international standards such as the
Guidelines International Network (GIN) - McMaster
guideline development checklist tool, rigorous methods,
combined with systematic and transparent processes, are
required by the ISS in its recently published methodo-
logical manual for CPGs development [4–6]. These regu-
lations have not been previously applied in Italian national
guidelines but are now a requirement in any CPG devel-
oped by ISS and, thus, in these two new ISS guidelines for
managing ASD.
Autism spectrum disorder and current guidelines on its
diagnosis and treatment in context
The essential behavioral features of ASD are persistent
impairment in reciprocal social communication and
social interaction and restricted, repetitive patterns of
behavior, interests, or activities. These core symptoms
are present from early childhood and limit or impair
everyday functioning [7], are extremely heterogeneous
both in terms of complexity and severity and vary over
time. Recent systematic review and large observational
research reported a prevalence of ASD in adults ranging
from 0.7 to 1.1% [8, 9], while a recent study performed
by the National Observatory for ASD (coordinated by
ISS and the Ministry of Health) revealed that approxi-
mately 1.3% of children in the age range 7 to 9 have
been diagnosed with ASD in Italy [10]. People with ASD
frequently present co-occurring neurological, psychiatric
and medical disorders that must be considered for the
organization of the appropriate interventions. Outcomes
related to interventions, both from tests and manage-
ment strategies, are typically reported by people with
ASD or caregivers. A considerable number of different
approaches to diagnose and manage ASD have been
proposed over the last 50 years. This reflects the com-
plexity of this condition, which requires a balance be-
tween medical, psychological, social, educational and
even ethical and existential needs. Many of these ap-
proaches have been object of academic and public de-
bate, often with overt disagreement between researchers,
clinicians, people with ASD, family and caregivers, and
other stakeholders [11, 12].
These factors represent challenges for the develop-
ment of evidence-based guidelines in this field. In 2011,
the ISS published the first Italian Guideline on ASD en-
titled ‘The treatment of children and adolescents with
ASD’. [13] The published recommendations have been
very controversially debated by professionals, institutions
and parents’ associations [14]. In 2015, a new law
demanded an update of these guidelines and the Italian
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Ministry of Health appointed the ISS to coordinate the
development of national guidelines on management of
ASD throughout the lifespan. As opposed to the previous
version, these new guidelines will also include diagnostic
questions and provide, separately, recommendations for
the population of children and adolescents with ASD and
for adults with ASD. Furthermore, these guidelines will
have to adhere to new methods outlined by CNEC within
the framework of the new SNLG and comply with its
innovations such as a policy for the disclosure and man-
agement of Conflict Of Interest (COI), transparent stake-
holder involvement and adoption of the GRADE approach
[15, 16]. Yet, these methods have not been tested in real
guideline development in this new legal framework.
Objectives of this article
This article introduces the methods and approach to
guideline development at the ISS, laying out its innova-
tive methods using the example of evidence-based guide-
lines for the diagnosis and management of ASD with a
focus on PROs.
Methods
The guideline development process was guided by the ISS
methodological manual [4] and derived from the GIN-
McMaster Guideline Development Checklist [6] (https://
cebgrade.mcmaster.ca/guidelinechecklistonline.html). It was
intended to meet recommendations for trustworthy guide-
lines by the National Academy of Medicine (U.S.), formerly
known as the Institute of Medicine, the World Health
Organization and the GIN [5, 17, 18].
Scope of the guideline
The Italian national law ‘Provisions on prevention, treat-
ment, and rehabilitation of people with autism spectrum
disorders, and assistance to families’ (Law 134, approved
by the Italian Government on August 2015) intends to
ensure the health, the improvement of living conditions
and the inclusion in social and working environments of
individuals with ASD. The two guidelines described here
will be developed in observance of the law 134. Their
scope includes the diagnosis and management of ASD
and requires describing the perspective, objectives, target
population, and target audience.
Participants in the process
The guideline working group benefits from the contribu-
tion of several teams. We describe their roles and re-
sponsibilities here.
The ISS Steering Committee (SC) leads and oversees
the development of the guideline, it defines the groups
involved (chairs, developers, panel, evidence review
team) and supports their productive interaction and it is
responsible for the development process including
budgeting, the definition of a timeline, and the manage-
ment of COI. The SC, coordinated by a principal investi-
gator and supported by scientific and technical secretariat,
selected two chairs for each guideline: one content expert
and one methodological expert. The chairs are included in
the SC together with a quality assurance team that ensures
the compliance of the development process with the ISS
methods and regulations.
The guideline group or panel is responsible for
prioritization of questions for the guideline, participation
in group meetings and teleconferences, providing input
on evidence and contextual factors, reviewing evidence
summaries, making judgments and formulating recom-
mendations in final panel meetings, reviewing and writing
of final guideline report and support for dissemination
[19]. Two separate panels have been selected, each focus-
ing on one of the ASD populations of interest: children/
adolescents and adults. Considering that the management
of ASD, from diagnosis to the delivery of comprehensive
care, involves a heterogeneous group of professionals and
competencies, the two panels were designed to be multi-
disciplinary and geographically representative of the entire
Italian territory. Through a public process [20], we invited
representatives of fields relevant to the guideline’s scope
with at least five years of experience and working for the
Italian national healthcare system (either in the local
health units or in the university/research hospitals) to vol-
untarily participate in the guidelines. The invitation in-
cluded representativeness of people with ASD and/or
their caregivers. Based on the analysis of their curriculum
vitae, cover letter and years of personal or professional ex-
perience in the ASD field, sixteen panel members have
been selected. All panel members have been invited to
sign a declaration of commitment and confidentiality and
fill in the COI form. The guideline methodologists or de-
velopers, trained in the GRADE approach and the use of
the GRADEpro Guideline Development Tool (GRADE-
pro, https://gradepro.org), work closely with the guideline
panel in prioritizing the relevant questions and outcomes,
prepare background documents for the guideline panel
and stakeholders, coordinate teleconferences and online
voting processes, review comments.
The Evidence Review Team (ERT) searches the litera-
ture and produces syntheses of the evidence. Following
the GRADE approach, the ERT rates the certainty in the
evidence, prepares the GRADE evidence tables and
Evidence-to-Decision (EtD) frameworks that the panels
use in formulating recommendations.
Management of conflict of interest
The ISS policy on the management of COI follows the
GIN principles for disclosure of interests and manage-
ment of COI in guidelines [18] and it is described in the
ISS manual [4]. According to this policy, those involved
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in the guideline development, including panel members,
the ERT, guideline developers and external referees, had
to declare all financial, non-financial, personal and insti-
tutional interests relevant to the scope of the guidelines
completing a standardized form. The SC evaluated each
individual interest based on its nature and type, specifi-
city with respect to the scope of guideline, financial
value, period and duration. If a declared interest was
deemed to represent a conflict, the following measures
for the management of COI were applied: full participa-
tion, with public disclosure of interest; partial exclusion
(e.g. exclusion from the works related to the declared
interest and from the relevant decision-making process);
total exclusion. We applied the policy throughout the
entire process, including during panel members selec-
tion, generation and prioritization of research questions,
and participation in the formulation of recommenda-
tions. We regularly monitored and updated declarations
of COI.
Opening meeting and training of the guideline panel
The working group met for the first time in a two-day
meeting held at the ISS headquarter. The following ac-
tivities took place: the SC outlined the scope of the
guideline; guideline developers presented the existing
guidelines on ASD; the working group discussed the re-
sources and time available and agreed to produce rec-
ommendations on 16 research questions for each of
the two ASD identified populations over an 18-month
time period. The guideline quality assurance team
presented the ISS policy on COI and collected COI
disclosure forms from participants. The ERT intro-
duced the GRADE methodology in two presentations.
The first presentation served as introduction to the
GRADE constructs of certainty in the evidence and
strength of recommendations [21, 22]. The second fo-
cused on GRADE evidence tables, GRADE EtD frame-
works and the importance of people’s values and
preferences in decision-making processes [23–26]. We
shared links to training material, including the ISS
manual and online resources on the GRADE ap-
proach to rating the certainty of evidence and the
EtD frameworks to meeting participants. The meeting
served for the members of the working group to get
to know each other and to commence collaboration.
Selection of guideline questions
We implemented a two-step approach that allowed
panels to identify and agree on the questions to be ad-
dressed in the guidelines using the module in GRADE-
pro that allows for the generation and prioritization of
questions and health outcomes [27].
Generation of questions
Guideline developers drafted a list of strategies and in-
terventions addressed in existing CPGs on the diagnosis
and management of ASD [28–31]. We discussed the list
during the opening meeting and invited panel members
to identify items missing or deemed not applicable to
the Italian context. Based on the output of the meeting,
subgroups including guideline developers and members
of the panel with specific expertise (content experts)
generated a list of candidate questions framed using the
PICO format (population, intervention, comparator, and
outcomes) [32]. To streamline the initial list, questions
were organized by category (e.g. questions pertaining to
the diagnosis, pharmacological, or psychosocial interven-
tions) and, where appropriate, grouped together. The
grouping was applied when interventions were assumed
to share similar functioning or having similar effects on
health outcomes (e.g. medications belonging to the same
drug class) and for similar diagnostic instruments. We
presented the list of candidate questions to the groups
during two-hour recorded web-based conferences.
Prioritisation of questions
Once the list of candidate questions was finalized, we
asked panels to rate the priority of questions on a 1 to 9
scale. We used surveys electronically generated in GRA-
DEpro (Fig. 1) and applied the following criteria: rating
Fig. 1 Rating question importance using GRADEpro. GRADEpro interface. Panel members rate the importance of candidate guideline questions
on a 1 to 9 scale. Lower ratings are indicative of lower importance
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of 7 to 9, high priority question - should be addressed in
the guideline; rating of 4 to 6, priority question but not
of high priority - should be listed as priority in the
guideline; rating of 1 to 3, not a priority question - it is
acceptable to neither include nor mention it in the
guideline.
We invited panel members to consider a brief list of
factors that typically influence whether a question is
relevant in the context of a CPG (Table 1).
We also provided supplementary materials including a
glossary of the acronyms used to formulate the questions
and articles related to the underpinning theoretical
frameworks considered to organize the questions into
categories. Following the rating exercise, we presented
the results (means, median, minimum and maximum) to
the groups in separate two-hour teleconferences using
the mean rating score as a ranking criterion. We invited
the groups to critically appraise the list and to evaluate
its harmony. In particular, we asked to verify if any of
the top-rated questions for inclusion could not be
considered as exhaustively informative to the reader if
not paired with another question that was not rated
for inclusion. To achieve harmony, we also organized
questions in sensible units, consisting of the smallest
recommendation sets that would be informative or
required for readers to avoid gaps and achieve rapid
dissemination [33]. We used the sensible units to
streamline the production and dissemination of rec-
ommendations and to create working sub-groups for
each, also known as the PICO Responsible Unit
(PRU), consisting of content experts and members of
the ERT [34].
Generation of outcomes
To determine the people-important outcomes to be ad-
dressed in the syntheses of the evidence, we first en-
gaged the PRUs in drafting descriptions of potentially
relevant desirable and undesirable outcomes. We created
written definitions of outcomes, known also as health
outcome descriptors, to reduce the risk of introducing
error that could result when panel members have differ-
ent understanding of the same outcomes. We then sent
GRADEpro surveys asking to add, for each question sep-
arately, potentially relevant people-important outcomes
that were not yet included in the list drafted by the
PRUs (Fig. 2).
Prioritisation of outcomes
We elicited ratings of the relative importance of out-
comes on a 1 to 9 scale (Fig. 3) in the corresponding
GRADEpro module. We asked the panels to rate out-
comes separately for each question using the following
criteria: a rating of 7 to 9, the outcome is critical for
decision-making; 4 to 6, the outcome is important but
not critical for decision-making; 1 to 3, the outcome is
of low importance for decision-making [35].
Similar to the question prioritization step, we provided
guidance materials on the task and its underpinning
concepts, available in additional file 1. We discussed the
results of the rating exercise (means, minimum and
maximum) in a face-to-face meeting using the mean rat-
ing score as the ranking criterion and considered only
outcomes rated as critical or important for inclusion in
systematic reviews and decision-making during formula-
tion of recommendations. Once the list of outcomes was
prioritized, we reached consensus on the final list of
questions as described above.
Stakeholders’ involvement
Public involvement in the development of ISS CPGs is
guaranteed through the participation of lay members in
the panel as well as also through a public consultation on
two key outputs of the process: draft list of guideline ques-
tions and draft recommendations. As for the former, we
made the list of prioritized questions available for com-
ments by stakeholders who met eligibility criteria. [36]
The stakeholders were organized in six categories: scien-
tific societies and health professions associations; family
associations and advocacy organizations; national and re-
gional public institutions (e.g. public universities); private
institutions (e.g. foundations, private health facilities, pri-
vate universities); industry (e.g. pharmaceutical compan-
ies); public and private research institutes.
Guideline panel members reviewed the comments that
were collected electronically using a structured question-
naire (https://piattaformasnlg.iss.it) over a four-week
period. Example of questions used in the questionnaire
are available in Additional file 2. This early involvement
aims at increasing transparency and stakeholder engage-
ment. Similarly, we will invite stakeholders to review and
provide comments on the draft recommendations once
they will become available. Our dissemination also in-
cludes a website (www.osservatorionazionaleautismo.it)
where recommendations and the underlying evidence will
be available for different user profiles, similar to those of
the European Commission Breast Guidelines [34].
Table 1 Factors that should be considered while deciding
which are the research questions to be included in a guideline
Factors that influence if a question is important in the context of a
guideline
1. Common question in practice?
2. Uncertainty in practice?
3. New evidence to consider?
4. Variation in practice?
5. Consequences for resource use/cost?
6. Not previously or sufficiently addressed?
Morgano et al. Health and Quality of Life Outcomes           (2020) 18:81 Page 5 of 12
Piloting of the development of recommendations
With the goal to allow the working group to gain experi-
ence with the process of making a recommendation and
to familiarize with the dynamics typical of guideline
panels, we identified two pilot research questions. The
ERT conducted systematic reviews and shared the follow-
ing materials in advance of panel discussion: GRADE Evi-
dence Profiles and a Summary of Findings tables [25, 26]
summarizing the effects of the interventions, an EtD
framework with structured summaries of the evidence to
address each criterion, the list of included and excluded
studies, and forest plots where applicable. We piloted the
decision-making process using both the in-person and the
online approach. In the former, panels met in a meeting
room equipped with a u-shaped table, microphones and a
recording system. A projector was used by the ERT to
present the synthesis of the evidence on a large screen and
by the chairs to facilitate discussion and navigate through
the various criteria of the EtD. Simultaneously, we also
streamed the meeting online using Webex (Cisco Webex,
https://www.webex.com/), to allow off-site participation
and visualization of content on the screen of panel mem-
bers’ devices while discussion it. To pilot the online ap-
proach, we used the PanelVoice module of GRADEpro
(https://gradepro.org/panel-voice/). Through electronic
surveys that are integrated in the EtDs, PanelVoice enables
guideline developers to facilitate the decision-making
process electronically. The process starts with the collec-
tion of panel judgments on the EtD criteria (Fig. 4).
Results of the PanelVoice are reported and agreement
reached through email interaction or other necessary.
The panel is then asked to decide and agree on the dir-
ection and strength of the recommendation and to for-
mulate the statements to be reported in the EtD
conclusions section (e.g. justification, implementation
considerations, research priorities etc.) (Fig. 5).
Results
Composition of the guideline panels
Between June and July 2018, the steering committee re-
ceived 158 applications for the two multidisciplinary and
multi-professional panels of independent experts. Twenty-
six applicants were not eligible because employed in private
healthcare facilities or universities, had undocumented de-
clared professional competences, their professional profile
was not requested in the public selection announcement,
or they applied after the submission deadline. Among the
138 who met the requirements, the SC selected 16 appli-
cants per panel on the basis of their professional and per-
sonal experience, expertise, healthcare setting (primary,
secondary and tertiary care), and geographical representa-
tion. Table 2 shows the compositions of the two panels.
Fig. 2 Generation of outcomes using GRADEpro. GRADEpro interface. Panel members suggest, separately for each question, any people-
important outcomes that should be considered during the rating of the relative importance of outcomes
Fig. 3 Rating relative importance of outcomes using GRADEpro. GRADEpro interface. Panel members rate the importance of people-important
outcomes on a 1 to 9 scale. Lower ratings are indicative of lower importance
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Management of Conflict of interest
The SC reviewed the detailed declarations of interest of
all the 158 candidate panelists. None of them was
prevented from participating in the panel because of
relevant COI, since all the interests declared were con-
sidered as manageable through measures such as partial
exclusion or public disclosure. Afterwards, the SC evalu-
ated the panelists’ declared and non-declared interests,
the latter identified through surveillance of research pro-
jects or training activities in which experts are engaged.
The SC did not identify any relevant COI that would
have prevented guideline panelists from participating in
the generation and selection of the research questions
addressed.
Guideline questions
We abstracted interventions and management strategies
from previous guidelines into 7 macro-areas to create an
initial list: diagnosis and assessment of ASD core-
symptoms, diagnosis and assessment of ASD associated
Fig. 4 Collection of EtD judgments using PanelVoice. PanelVoice/GRADEpro interface. Judgments on the EtD criteria submitted by panel
members are visible to guideline developers and can be used to facilitate the decision-making process online
Fig. 5 Collection of votes on the strength and direction of recommendations using the GRADEpro/PanelVoice interface. Voting results for the
direction and strength of the recommendation are visible to guideline developers and can be used to reach online agreement about the
final recommendation
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features, comorbidities, differential diagnosis, pharmaco-
logical interventions, psychosocial interventions, other non-
pharmacological interventions. Strategies within the same
macro-area were categorized and grouped together by the
PRU where applicable. Categorization was based on the tar-
get population (e.g. people with ASD versus their care-
givers) and on the theory underpinning the interventions.
Due to the availability of multiple theoretical frameworks
related to non-pharmacological interventions for ASD, the
latter categorization presented challenges that we solved
through discussion. As for the population of children and
adolescents with ASD, the process resulted in a list of 79
questions of which 27 were high-priority, 46 questions im-
portant, and 6 questions not important. As for adults, we
generated a list of 31 questions of which 21 were high-
priority and 10 questions important. For each population,
we will develop recommendations to answer 16 research
questions whereas all other questions will be mentioned as
not prioritized in the guideline. Tables 3 and 4 lists the
questions prioritized for inclusion in the guidelines. The
lists of all generated questions and their priority ratings are
available in Additional file 3.
Outcomes
The panel responsible for children and adolescents with
ASD rated ASD core-symptoms as critical outcomes for all
research questions. Impairments in social interaction and
communication, and restricted and repetitive behaviors
were considered as distinct core-symptoms of ASD and
rated separately. Other critical and important outcomes









Childhood neuro and psychomotricity therapist 1 –
Speech therapist 1 –
Pedagogues 1 1
Social worker – 1
Educational therapist 1 1
Occupational therapist – 2
Expert in the management of healthcare systems 1 1
General practitioner 1 1
Pediatrician 1 –
Methodologist 1 1
Parent of child or adolescents with ASD 2 1
Person with ASD – 1
Table 3 List of questions included in the guideline on children
and adolescents with ASD
Question Macro-area
1 Should structured diagnostic instruments
(administered to the children) be added
to the clinical assessment from a
multidisciplinary team to diagnose ASD
core symptoms?
Diagnosis
2 Should structured diagnostic instruments
(administered to the parents or caregivers)
be added to the clinical assessment from a
multidisciplinary team to diagnose ASD
core symptoms?
Diagnosis
3 Which are the most prevalent comorbidities
in children and adolescents with ASD?
Diagnosis
4 Should INEC comprehensive individual vs
no intervention or treatment as usual




5 Should ABA comprehensive vs no
intervention or treatment as usual be used
for children and adolescents with ASD?
Psychosocials
interventions
6 Should Educational comprehensive
individual vs no intervention or treatment




7 Should interventions with parents/
caregivers vs no intervention or treatment




8 Should INEC focalized vs no intervention
or treatment as usual be used for children
and adolescents with ASD?
Psychosocials
interventions
9 Should ABA focalized vs no intervention
or treatment as usual be used for children
and adolescents with ASD?
Psychosocials
interventions
10 Should INEC focalized vs no intervention
or treatment as usual be used for children
and adolescents with ASD?
Psychosocials
interventions
11 Should mood stabilizers vs no intervention




12 Should SSRIs and/or SNRIs vs no SSRIs




13 Should D2 blockers vs no D2 blockers be
used in children and adolescents with ASD?
Pharmacological
interventions
14 Should psychostimulants and/or atomoxetine
vs no psychostimulants and/or atomoxetine
be used in children and adolescents with ASD?
Pharmacological
interventions
15 Should communicative interventions for
social communication and interaction vs
no intervention or treatment as usual
be used in children and adolescents
with ASD?
Other interventions
16 Should interventions for specific behaviours
vs no intervention or treatment as usual be
used in children and adolescents with ASD?
Other interventions
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included quality of life, adaptive functioning skills, and par-
enting stress. The panel responsible for adults with ASD
prioritized outcomes related to quality of life and outcomes
such as social inclusion, level of independency from the
caregivers, overall functioning and professional competen-
cies. Other important outcomes included core-symptoms,
behavioral disturbances, psychotic symptoms and treat-
ments’ side effects. All outcomes were PROs.
Stakeholders’ consultation on the research questions
Of the 129 stakeholders that requested to comment on
the list of questions identified for inclusion in the guide-
line, 115 met the eligibility criteria. We excluded stake-
holders for the following reasons: the application
process was not completed or the relationship with
healthcare industries was not declared. Figure 6 shows
the distribution of registered stakeholders.
The majority of comments pertained to potentially
relevant subgroups and outcomes that were not consid-
ered in the prioritized guideline questions. Many stake-
holders requested clarification regarding the meaning of
“standard of care” which was used to phrase some of the
questions. Based on the feedback received, we reviewed
the comments and improved the wording of research
questions and added new sub-groups, where necessary.
Piloting of the development of recommendations
The questions identified for piloting the process focused
on the impact of polyunsaturated fatty acids on PROs in
children and adolescents with ASD. The body of evi-
dence consisted of Randomized Controlled Trials
(RCTs) and the overall certainty in the estimated effects
was rated as very low owing to serious indirectness and
very serious imprecision. Based on the very low certainty
in the evidence of effects and uncertainty in other judg-
ments on EtD criteria, the panel made conditional rec-
ommendations. Further details on the pilot questions,
including the EtD framework with panel judgments, are
available in Additional file 4.
Discussion
We have described the methods and processes for guide-
line development at the ISS using the diagnosis and
management of people with ASD as an example. It is the
first guideline that follows the new ISS standards and
has posed a number of methodological challenges that
we addressed using novel guideline development ap-
proaches [4]. A challenge particularly relevant to ASD is
its focus on PROs in people living in the ASD spectrum
and their caregivers.
Challenges encountered during the development process
The heterogenous composition of the panels, which in-
cludes health professionals and stakeholders across a
broad spectrum, reflects the complexity of the condition
being addressed. The management of such large guide-
line groups, which encompass different professionals
and potentially heterogeneous viewpoints, requires par-
ticular ability by chairpersons to conduct effective meet-
ings. Given the broad interest in this guideline by many
and diverse stakeholder groups, the process requires
maximum possible transparency and we tackled this
challenge through the use of GRADE EtDs, the early
Table 4 List of questions included in the guideline on adults
with ASD
Question Macro-area
1 Should structured diagnostic instruments
be added to routine clinical assessment
to diagnose ASD in adults?
Diagnosis
2 Should structured diagnostic instruments
to assess psichoeducative and adaptive
profile be added to the clinical assessment
of the adults with ASD?
Diagnosis
3 Should structured diagnostic instruments
to assess neuropsychological and cognitive
profile be added to the clinical assessment
of the adults with ASD?
Diagnosis
4 Should tests or diagnostic examinations
be used to identify psychiatric, neurologic
and/or selected medical comorbidities in
adults with ASD?
Diagnosis
5 Should standardized instruments to rate
the quality of life be used in clinical routine
for adults with ASD?
Psychosocials
interventions
6 Should standardized preference procedures




7 Should community-based services and
housing support be taken into
consideration for adults with ASD?
Psychosocials
interventions
8 Should psychoeducative programs
be implemented in adults with ASD?
Psychosocials
interventions
9 Should information/support campaigns
for family members, caregivers and
other public figures be accomplished
in support of adults with ASD?
Psychosocials
interventions
10 Should interventions in support of
occupational activities be implemented
in adults with ASD?
Psychosocials
interventions
11 Should psychological interventions
be implemented in adults with ASD?
Psychosocials
interventions
12 Should antipsychotics vs no antipsychotics
be used in adults with ASD?
Pharmacological
interventions
13 Should mood stabilizers vs no mood
stabilizers be used in adults with ASD?
Pharmacological
interventions
14 Should antidepressants vs no




15 Should stimulants vs no stimulants
be used in adults with ASD?
Pharmacological
interventions
16 Should “other drugs” vs no “other
drugs” be used in adults with ASD?
Pharmacological
interventions
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involvement of key stakeholders and press releases. Ap-
plying the ISS COI policy revealed the need for a cul-
tural change. In fact, experts are often not aware that
having published on the topic of interest or carried out
research or professional activities in the field constitute
an interest to be declared. This is important not only for
disclosure purposes but also for allowing an assessment
of potential conflicts and for determining measures to
manage them. We provided guidance to experts in this
process to enable them to recognize and declare any cir-
cumstance in which a secondary interest could interfere
with the impartial performance of their duties, functions
and tasks.
Strengths and innovations of this guideline development
process
We created a large multidisciplinary panel which include
people with ASD and their caregivers and operate under a
transparent policy on COI. Our process for prioritization,
using a structured and transparent approach, granted
equal voices to panel members and focused on PROs.
Our process is supported by independent systematic re-
views by the ERT which include an assessment of the
certainty in the evidence according to the GRADE ap-
proach. We used health outcome descriptors to
minimize the bias and improve the overall transparency
of the process. Using the GRADE EtD framework, cri-
teria and judgments that yield recommendations are
transparent and allow targeting to different user pro-
files [34]. Through training and piloting exercises, we
allowed the panel acquired familiarity with the GRADE
approach, the use of the EtD framework, and the sum-
maries of evidence provided to make informed judg-
ments and reach recommendations.
We used information technology to streamline the de-
velopment process and improve efficiency. Indeed, web-
based decision-making and communication tools such as
of GRADEpro, StarLeaf, and Webex facilitated work lo-
gistics and decreased costs associated with in-person
meetings while increasing panel members’ involvement.
We promoted stakeholders’ involvement from early
stages of the process. The ISS SNLG web platform en-
sured a transparent and participative process in which
stakeholders are empowered to provide valuable feed-
back in several phases of the process.
Limitations of this guideline development process
Guideline development requires advanced methodo-
logical skills and understanding of evidence. Although
panel members are not formally required to know the
details of methodology, they must get acquainted with
the relevant principles in order to understand the
process flow; an ability which demands appropriate
training. Human and time resources to develop the syn-
theses of the evidence that are used to inform the guide-
line are a very relevant component of the development
process but these resources are small compared to the
cost of treatment and primary research in this area.
Conclusions
We have described the new Italian national guideline de-
velopment process during its first application in recom-
mendations about the diagnosis and management of
ASD. The process seems feasible and acceptable to key
stakeholders, including guideline panel members, those
synthesizing the evidence and the public. The guideline
working group is now developing recommendations that
will be disseminated and adopted in Italy. This guideline
aims to serve as a reference standard for future guideline
development in the Italian setting, and it will allow the
adoption or adaptation to various settings, including
international jurisdictions.
Fig. 6 Distribution of registered stakeholders. Pie chart reporting affiliations of the stakeholders participating in the public consultation
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